Literature DB >> 17466898

Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis.

Patricia Harnden1, Mike D Shelley, Bernadette Coles, John Staffurth, Malcom D Mason.   

Abstract

The Gleason system for grading prostate cancer assigns a score on the basis of the most prevalent and second most prevalent grade. Several studies have investigated the clinical significance of a tertiary grade in radical prostatectomy samples. A systematic search of the published work identified seven studies that reported the prognostic value of a tertiary Gleason grade. Three studies correlated the presence of a tertiary grade with pathological stage, and six with prostate-specific antigen recurrence or clinical progression. In the small number of studies available, the frequency of a tertiary grade was consistently higher in samples characterised with pathological variables of poor outcome, such as extra-prostatic extension and positive surgical margins, but not lymph-node metastases. In five studies the presence of a tertiary grade increased the risk of prostate-specific antigen recurrence after radical prostatectomy by a factor of 2.5. However, modification of the Gleason score to include a tertiary grade in Gleason 4+3 tumours might overestimate the risk of seminal-vesicle or lymph-node invasion. This systematic review has established the association of a tertiary grade with poorer outcome than that associated with no tertiary grade. A tertiary grade should, therefore, be included in the pathological reporting of prostate cancer and be considered in the interpretation and design of clinical trials. However, all studies assessed for this review were retrospective, potentially affected by selection bias, and based on radical prostatectomy samples or transurethral resections rather than biopsy samples. Therefore, more evidence is needed to warrant the adaptation of the Gleason system to account for the presence of a tertiary grade, especially when scoring prostatic biopsies and applying predictive algorithms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17466898     DOI: 10.1016/S1470-2045(07)70136-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  13 in total

1.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

2.  Automated prostate tissue referencing for cancer detection and diagnosis.

Authors:  Jin Tae Kwak; Stephen M Hewitt; André Alexander Kajdacsy-Balla; Saurabh Sinha; Rohit Bhargava
Journal:  BMC Bioinformatics       Date:  2016-06-01       Impact factor: 3.169

3.  Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?

Authors:  Silvan Boxler; Valentin Djonov; Thomas M Kessler; Ruslan Hlushchuk; Lucas M Bachmann; Ulrike Held; Regula Markwalder; George N Thalmann
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

4.  Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancer.

Authors:  Michael Goodman; Kevin C Ward; Adeboye O Osunkoya; Milton W Datta; Daniel Luthringer; Andrew N Young; Katerina Marks; Vaunita Cohen; Jan C Kennedy; Michael J Haber; Mahul B Amin
Journal:  Prostate       Date:  2012-01-06       Impact factor: 4.104

5.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

6.  The evolving biology and treatment of prostate cancer.

Authors:  Russel S Taichman; Robert D Loberg; Rohit Mehra; Kenneth J Pienta
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system.

Authors:  Bruce J Trock; Charles C Guo; Mark L Gonzalgo; Ahmed Magheli; Stacy Loeb; Jonathan I Epstein
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

8.  Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer.

Authors:  Changhee Yoo; Cheol Young Oh; Jin Seon Cho; Cheryn Song; Seong Il Seo; Hanjong Ahn; Tae-Kon Hwang; Jun Cheon; Kang Hyun Lee; Tae Gyun Kwon; Tae Young Jung; Moon Kee Chung; Sang Eun Lee; Hyun Moo Lee; Eun Sik Lee; Young Deuk Choi; Byung Ha Chung; Hyung Jin Kim; Wun-Jae Kim; Seok-Soo Byun; Han Yong Choi
Journal:  J Korean Med Sci       Date:  2011-03-28       Impact factor: 2.153

9.  TRPV6 alleles do not influence prostate cancer progression.

Authors:  Thorsten Kessler; Ulrich Wissenbach; Rainer Grobholz; Veit Flockerzi
Journal:  BMC Cancer       Date:  2009-10-26       Impact factor: 4.430

10.  Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction.

Authors:  Ricardo J T Ribeiro; Cátia P D Monteiro; Andreia S M Azevedo; Virgínia F M Cunha; Agnihotram V Ramanakumar; Avelino M Fraga; Francisco M Pina; Carlos M S Lopes; Rui M Medeiros; Eduardo L Franco
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.